Effect of high-dose Spirulina supplementation on hospitalized adults with COVID-19: a randomized controlled trial
Frontiers in Immunology · 2024
DOI: 10.3389/fimmu.2024.1332425 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Frontiers in Immunology, 2024. Verfasst von Mohammad Reza Aghasadeghi und 25 weiteren Autor:innen. Beteiligte Einrichtung: Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran. Hauptthemen laut MEDLINE: Spirulina, Dietary Supplements, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Spirulina ( arthrospira platensis ) is a cyanobacterium proven to have anti-inflammatory, antiviral, and antioxidant effects. However, the effect of high-dose Spirulina supplementation on hospitalized adults with COVID-19 is currently unclear. This study aimed to evaluate the efficacy and safety of high-dose Spirulina platensis for SARS-CoV-2 infection. Study Design We conducted a randomized, controlled, open-label trial involving 189 patients with COVID-19 who were randomly assigned in a 1:1 ratio to an experimental group that received 15.2g of Spirulina supplement plus standard treatment (44 non-intensive care unit (non-ICU) and 47 ICU), or to a control group that received standard treatment alone (46 non-ICU and 52 ICU). The study was conducted over six days. Immune mediators were monitored on days 1, 3, 5, and 7. The primary outcome of this study was mortality or hospital discharge within seven days, while the overall discharge or mortality was considered the secondary outcome.
Results
Within seven days, there were no deaths in the Spirulina group, while 15 deaths (15.3%) occurred in the control group. Moreover, within seven days, there was a greater number of patients discharged in the Spirulina group (97.7%) in non-ICU compared to the control group (39.1%) (HR, 6.52; 95% CI, 3.50 to 12.17). Overall mortality was higher in the control group (8.7% non-ICU, 28.8% ICU) compared to the Spirulina group (non-ICU HR, 0.13; 95% CI, 0.02 to 0.97; ICU, HR, 0.16; 95% CI, 0.05 to 0.48). In non-ICU, patients who received Spirulina showed a significant reduction in the levels of IL-6, TNF-α, IL-10, and IP-10 as intervention time increased. Furthermore, in ICU, patients who received Spirulina showed a significant decrease in the levels of MIP-1α and IL-6. IFN-γ levels were significantly higher in the intervention group in both ICU and non-ICU subgroups as intervention time increased. No side effects related to Spirulina supplements were observed during the trial.
Conclusion
High-dose Spirulina supplements coupled with the standard treatment of COVID-19 may improve recovery and remarkably reduce mortality in hospitalized patients with COVID-19. Clinical Trial Registration https://irct.ir/trial/54375 , Iranian Registry of Clinical Trials number (IRCT20210216050373N1)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran.
- Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran.
- Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
- Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Infectious Disease, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Aghasadeghi, M. R., Zaheri Birgani, M. A., Jamalimoghadamsiyahkali, S., Hosamirudsari, H., Moradi, A., Jafari-Sabet, M., Sadigh, N., Rahimi, P., Tavakoli, R., Hamidi-Fard, M., Bahramali, G., Parmoon, Z., Arjmand Hashjin, S., Mirzajani, G., Kouhkheil, R., Roshangaran, S., Khalaf, S., Khademi Nadoushan, M., Gholamiyan Yousef Abad, G., …, & Hackett, D. (2024). Effect of high-dose Spirulina supplementation on hospitalized adults with COVID-19: a randomized controlled trial. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2024.1332425
Vancouver
Aghasadeghi MR, Zaheri Birgani MA, Jamalimoghadamsiyahkali S, Hosamirudsari H, Moradi A, Jafari-Sabet M, et al. Effect of high-dose Spirulina supplementation on hospitalized adults with COVID-19: a randomized controlled trial. Frontiers in Immunology. 2024. doi:10.3389/fimmu.2024.1332425
BibTeX
@article{Aghasadeghi2024,
author = {Aghasadeghi, Mohammad Reza and Zaheri Birgani, Mohammad Ali and Jamalimoghadamsiyahkali, Saeedreza and Hosamirudsari, Hadiseh and Moradi, Ali and Jafari-Sabet, Majid and Sadigh, Nooshin and Rahimi, Pooneh and Tavakoli, Rezvan and Hamidi-Fard, Mojtaba and Bahramali, Golnaz and Parmoon, Zohal and Arjmand Hashjin, Sina and Mirzajani, Ghasem and Kouhkheil, Reza and Roshangaran, Somayeh and Khalaf, Samineh and Khademi Nadoushan, Mohammad and Gholamiyan Yousef Abad, Ghazaleh and Shahryarpour, Nima and Izadi, Mohammad and Zendedel, Abolfazl and Jahanfar, Shayesteh and Dadras, Omid and SeyedAlinaghi, SeyedAhmad and Hackett, Daniel},
title = {Effect of high-dose Spirulina supplementation on hospitalized adults with COVID-19: a randomized controlled trial},
journal = {Frontiers in Immunology},
year = {2024},
doi = {10.3389/fimmu.2024.1332425}
}
EUVIMED